Nektar Therapeutics to Participate in Two Investor Conferences in September
Rhea-AI Summary
Nektar Therapeutics (NASDAQ:NKTR) announced its participation in two upcoming investor conferences in September 2025. The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 at 10:30 AM ET in New York City, and the Stifel Virtual Immunology and Inflammation Forum on September 15 at 2:30 PM ET.
Both presentations will be available via webcast through the company's investor relations website, with replays accessible for 30 days. Investors interested in one-on-one meetings with management can arrange them through their representatives.
Positive
- None.
Negative
- None.
News Market Reaction – NKTR
On the day this news was published, NKTR gained 26.02%, reflecting a significant positive market reaction. Argus tracked a peak move of +20.0% during that session. Our momentum scanner triggered 48 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $143M to the company's valuation, bringing the market cap to $691M at that time. Trading volume was very high at 4.7x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
- H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025 – webcast to be available at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time – link here
- Stifel 2025 Virtual Immunology and Inflammation Forum on Monday, September 15, 2025 – webcast to be available at 2:30 p.m. Eastern Time / 11:30 a.m. Pacific Time – link here
The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. Replays of the presentations will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-september-302545833.html
SOURCE Nektar Therapeutics
FAQ
When is Nektar Therapeutics (NKTR) presenting at the H.C. Wainwright Conference 2025?
When is NKTR's presentation at the Stifel Virtual Immunology Forum 2025?
How can investors access Nektar's (NKTR) September 2025 conference presentations?
How can investors schedule meetings with Nektar management at these conferences?
